東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Blood-brain barrier in drug discover...

Di, Li.

Linked to FindBook

Google Book

Amazon

博客來

Blood-brain barrier in drug discovery = optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Blood-brain barrier in drug discovery/ edited by Li Di, Edward H. Kerns.
Reminder of title:	optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs /
remainder title:	Optimizing brain exposure of central nervous system drugs and minimizing brain side effects for peripheral drugs
other author:	Di, Li.
Published:	Hoboken, New Jersey :John Wiley & Sons Inc., : 2015.,
Description:	1 online resource :col. ill.
Notes:	Wiley online library (ebook collection)
[NT 15003449]:	Machine generated contents note: Summary List of Chapters1. Overview/Introduction / Li Di (Pfizer Inc.), Edward H. Kerns (Pharmacokinetics of Brain Exposure)2. Pharmacokinetics of CNS penetration / Andreas Reichel (Bayer)3. Free Drug Hyposthesis for CNS Drug Candidates / Xingrong Liu (Genentech)4. Species Differences and impact of desease state on BBB / Jean-Marie Nicolas (UCB Pharma S.A.)Mechanisms of Drugs Across the Blood-Brain Barrier5. Passive diffusion permeability of the BBB -- examples and SAR / Phil Jeffrey (GSK)6. Efflux transport at the BBB -- examples and SAR / Jerome Hochman (Merck)7. Uptake transport at the BBB -- examples and SAR / Zack Cheng (AstraZeneca)8. Uptake of proteins and antibodies at the BBB / William Pardridge (UCLA)Predicting and Measuring Brain Exposure of Drugs9. In silico tools for assessing brain exposure / Hongming Chen (AstraZeneca)10. In vitro assays for assessing BBB permeability -- vascular cells, artificial membranes, brain slice, cell uptake / Winfried Neuhaus (University of Vienna)11. Human-based in vitro endothelial cell models / Eric Shusta (University of Wisconsin)12. In vitro assays for assessing brain binding / Li Di (Pfizer)13. In vivo studies of brain exposure / Edward H. Kerns14. PBPK models for BBB / Elizabeth de Lange (Leiden University)15. PK/PD modeling of CNS drug candidates / Johan Gabrielsson (Swedish University)16. Microdialysis to assess free drug concentration in brain / William Kielbasa (Lilly)17. Imaging technique for CNS drug discovery / Lei Zhang (Pfizer Inc.)Modulating Brain Penetration of Leads During Drug Discovery18. Designing CNS drugs for optimal brain exposure / Zoran Rankovic (Lilly)19. Case studies of CNS drug optimization -- medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts (Harvard NeuroDiscovery Center)20. Designing peripheral drugs for minimal brain exposue / Peter Bungay (Pfizer)21. Case studies of non-CNS drugs to minimize brain penetration -- Nonsudative antihistamines / Andrew Crowe (Curtin University)Case Studies in CNS Drug Discovery22. Case study 1 on discovery of a successful CNS drug -- Fycompa (AMPA Receptor Antagonist) / Andrew Satlin and Antonio Laurenza (Eisai)23. Case study 2 on discovery of a successful CNS drug -- Vortioxetine (Serotonin Modulator and Stimulator) / Benny Bang-Andersen (Lundbeck)Drug Delivery Techniques to CNS24. Brain delivery using nanotechnology / Xinguo Jiang (Fudan University)25. Intranasal delivery to CNS / Lisbeth Illum (University of Nottingham)Future Prospective in Blood Brain Barrier Advancement26. Conclusion Remarks / Joan Abbott (King's College).
Subject:	Blood-brain barrier - Metabolism. -
Online resource:	http://onlinelibrary.wiley.com/book/10.1002/9781118788523
ISBN:	9781118788547

Blood-brain barrier in drug discovery = optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs /
Blood-brain barrier in drug discoveryoptimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs /[electronic resource] :Optimizing brain exposure of central nervous system drugs and minimizing brain side effects for peripheral drugsedited by Li Di, Edward H. Kerns. - Hoboken, New Jersey :John Wiley & Sons Inc.,2015. - 1 online resource :col. ill.

Wiley online library (ebook collection)

Includes bibliographical references and index.

Machine generated contents note: Summary List of Chapters1. Overview/Introduction / Li Di (Pfizer Inc.), Edward H. Kerns (Pharmacokinetics of Brain Exposure)2. Pharmacokinetics of CNS penetration / Andreas Reichel (Bayer)3. Free Drug Hyposthesis for CNS Drug Candidates / Xingrong Liu (Genentech)4. Species Differences and impact of desease state on BBB / Jean-Marie Nicolas (UCB Pharma S.A.)Mechanisms of Drugs Across the Blood-Brain Barrier5. Passive diffusion permeability of the BBB -- examples and SAR / Phil Jeffrey (GSK)6. Efflux transport at the BBB -- examples and SAR / Jerome Hochman (Merck)7. Uptake transport at the BBB -- examples and SAR / Zack Cheng (AstraZeneca)8. Uptake of proteins and antibodies at the BBB / William Pardridge (UCLA)Predicting and Measuring Brain Exposure of Drugs9. In silico tools for assessing brain exposure / Hongming Chen (AstraZeneca)10. In vitro assays for assessing BBB permeability -- vascular cells, artificial membranes, brain slice, cell uptake / Winfried Neuhaus (University of Vienna)11. Human-based in vitro endothelial cell models / Eric Shusta (University of Wisconsin)12. In vitro assays for assessing brain binding / Li Di (Pfizer)13. In vivo studies of brain exposure / Edward H. Kerns14. PBPK models for BBB / Elizabeth de Lange (Leiden University)15. PK/PD modeling of CNS drug candidates / Johan Gabrielsson (Swedish University)16. Microdialysis to assess free drug concentration in brain / William Kielbasa (Lilly)17. Imaging technique for CNS drug discovery / Lei Zhang (Pfizer Inc.)Modulating Brain Penetration of Leads During Drug Discovery18. Designing CNS drugs for optimal brain exposure / Zoran Rankovic (Lilly)19. Case studies of CNS drug optimization -- medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts (Harvard NeuroDiscovery Center)20. Designing peripheral drugs for minimal brain exposue / Peter Bungay (Pfizer)21. Case studies of non-CNS drugs to minimize brain penetration -- Nonsudative antihistamines / Andrew Crowe (Curtin University)Case Studies in CNS Drug Discovery22. Case study 1 on discovery of a successful CNS drug -- Fycompa (AMPA Receptor Antagonist) / Andrew Satlin and Antonio Laurenza (Eisai)23. Case study 2 on discovery of a successful CNS drug -- Vortioxetine (Serotonin Modulator and Stimulator) / Benny Bang-Andersen (Lundbeck)Drug Delivery Techniques to CNS24. Brain delivery using nanotechnology / Xinguo Jiang (Fudan University)25. Intranasal delivery to CNS / Lisbeth Illum (University of Nottingham)Future Prospective in Blood Brain Barrier Advancement26. Conclusion Remarks / Joan Abbott (King's College).

"Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher.

ISBN: 9781118788547

LCCN: 2014041569Subjects--Topical Terms:

2118276
Blood-brain barrier
--Metabolism.

LC Class. No.: RM315

Dewey Class. No.: 615.7/8

National Library of Medicine Call No.: WL 200

Blood-brain barrier in drug discovery = optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs /
LDR:05074cmm a2200373 i 4500 001 1978678
003 OCoLC
005 20150310094645.0
006 m o d
007 cr |||||||||||
008 150610s2015 njua ob 001 0 eng
010 $a 2014041569
020 $a 9781118788547 $q electronic bk.
020 $a 1118788540 $q electronic bk.
020 $a 9781118788523 $q electronic bk.
020 $a 1118788524 $q electronic bk.
020 $z 9781118788493
020 $z 1118788494
020 $z 9781118788356 $q hardback
020 $z 1118788354 $q hardback
035 $a (OCoLC)893389733
040 $a DLC $b eng $c DLC $d N $d DG1 $d N $d YDXCP $d E7B
050 1 0 $a RM315
060 1 0 $a WL 200
082 0 0 $a 615.7/8 $2 23
245 0 0 $a Blood-brain barrier in drug discovery $h [electronic resource] : $b optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs / $c edited by Li Di, Edward H. Kerns.
246 3 $a Optimizing brain exposure of central nervous system drugs and minimizing brain side effects for peripheral drugs
260 $a Hoboken, New Jersey : $b John Wiley & Sons Inc., $c 2015.
300 $a 1 online resource : $b col. ill.
500 $a Wiley online library (ebook collection)
504 $a Includes bibliographical references and index.
505 8 $a Machine generated contents note: Summary List of Chapters1. Overview/Introduction / Li Di (Pfizer Inc.), Edward H. Kerns (Pharmacokinetics of Brain Exposure)2. Pharmacokinetics of CNS penetration / Andreas Reichel (Bayer)3. Free Drug Hyposthesis for CNS Drug Candidates / Xingrong Liu (Genentech)4. Species Differences and impact of desease state on BBB / Jean-Marie Nicolas (UCB Pharma S.A.)Mechanisms of Drugs Across the Blood-Brain Barrier5. Passive diffusion permeability of the BBB -- examples and SAR / Phil Jeffrey (GSK)6. Efflux transport at the BBB -- examples and SAR / Jerome Hochman (Merck)7. Uptake transport at the BBB -- examples and SAR / Zack Cheng (AstraZeneca)8. Uptake of proteins and antibodies at the BBB / William Pardridge (UCLA)Predicting and Measuring Brain Exposure of Drugs9. In silico tools for assessing brain exposure / Hongming Chen (AstraZeneca)10. In vitro assays for assessing BBB permeability -- vascular cells, artificial membranes, brain slice, cell uptake / Winfried Neuhaus (University of Vienna)11. Human-based in vitro endothelial cell models / Eric Shusta (University of Wisconsin)12. In vitro assays for assessing brain binding / Li Di (Pfizer)13. In vivo studies of brain exposure / Edward H. Kerns14. PBPK models for BBB / Elizabeth de Lange (Leiden University)15. PK/PD modeling of CNS drug candidates / Johan Gabrielsson (Swedish University)16. Microdialysis to assess free drug concentration in brain / William Kielbasa (Lilly)17. Imaging technique for CNS drug discovery / Lei Zhang (Pfizer Inc.)Modulating Brain Penetration of Leads During Drug Discovery18. Designing CNS drugs for optimal brain exposure / Zoran Rankovic (Lilly)19. Case studies of CNS drug optimization -- medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts (Harvard NeuroDiscovery Center)20. Designing peripheral drugs for minimal brain exposue / Peter Bungay (Pfizer)21. Case studies of non-CNS drugs to minimize brain penetration -- Nonsudative antihistamines / Andrew Crowe (Curtin University)Case Studies in CNS Drug Discovery22. Case study 1 on discovery of a successful CNS drug -- Fycompa (AMPA Receptor Antagonist) / Andrew Satlin and Antonio Laurenza (Eisai)23. Case study 2 on discovery of a successful CNS drug -- Vortioxetine (Serotonin Modulator and Stimulator) / Benny Bang-Andersen (Lundbeck)Drug Delivery Techniques to CNS24. Brain delivery using nanotechnology / Xinguo Jiang (Fudan University)25. Intranasal delivery to CNS / Lisbeth Illum (University of Nottingham)Future Prospective in Blood Brain Barrier Advancement26. Conclusion Remarks / Joan Abbott (King's College).
520 $a "Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher.
588 0 $a Description based on online resource; title from PDF title page (EBSCO, viewed January 9, 2015).
650 0 $a Blood-brain barrier $x Metabolism. $3 2118276
650 0 $a Drug development. $3 716904
650 2 $a Blood-Brain Barrier $x metabolism. $3 2118277
650 2 $a Central Nervous System Agents $x pharmacokinetics. $3 2118278
650 2 $a Blood-Brain Barrier $x drug effects. $3 2118279
650 2 $a Central Nervous System Diseases $x drug therapy. $3 1364741
650 2 $a Drug Discovery $x methods. $3 1305509
650 2 $a Drug-Related Side Effects and Adverse Reactions $x prevention & control. $3 2118280
700 1 $a Di, Li. $3 885143
700 1 $a Kerns, Edward Harvel. $3 885144
856 4 0 $u http://onlinelibrary.wiley.com/book/10.1002/9781118788523